How Qualitative Methods Can be Used to Inform Model Development.

abstract：OBJECTIVE:The objective of this study was to assess the cost effectiveness of using epoetin-alpha (erythropoietin) to augment preoperative autologous donation (PAD) of blood prior to elective cardiac surgery. DESIGN AND SETTING:We designed a decision-analytic model incorporating the risk of receiving allogeneic blood,...

journal_title：PharmacoEconomics

authors： Coyle D,Lee KM,Fergusson DA,Laupacis A

更新日期：2000-08-01 00:00:00

abstract：:Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for the analysis. National gu...

journal_title：PharmacoEconomics

authors： Rappange DR,van Baal PH,van Exel NJ,Feenstra TL,Rutten FF,Brouwer WB

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:The measurement and valuation of health-related quality of life for and by young people are increasingly important, yet research on the impact of study perspective and validity of preferences obtained from young populations remains limited. OBJECTIVE:The objective of this study was to evaluate the feasibili...

journal_title：PharmacoEconomics

authors： Dalziel K,Catchpool M,García-Lorenzo B,Gorostiza I,Norman R,Rivero-Arias O

更新日期：2020-05-01 00:00:00

abstract：:Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

journal_title：PharmacoEconomics

authors： Bermejo I,Tappenden P,Youn JH

更新日期：2017-11-01 00:00:00

abstract：OBJECTIVE:To decompose drug spending in Sweden between the years 1990 and 2000. This paper updates a previous study, which looked at the period 1990-1995, by providing an additional 5 years of data (1995-2000) and extending the previous analysis in a number of ways. METHODS:The paper builds on the earlier work that sh...

journal_title：PharmacoEconomics

authors： Gerdtham UG,Lundin D

更新日期：2004-01-01 00:00:00

abstract：:In an effort to control escalating health expenditures, especially in hospitals, many countries are planning or experimenting with prospective budgeting systems. Belgium is no exception and has recently introduced, with some success, limited fixed charges per hospital admission and/or per hospitalisation day for labor...

journal_title：PharmacoEconomics

authors： Closon MC,Crott R,Even-Adin D

更新日期：1996-03-01 00:00:00

abstract：:This tutorial presents practical guidance on transforming various types of information published in journals, or available online from government and other sources, into transition probabilities for use in state-transition models, including cost-effectiveness models. Much, but not all, of the guidance has been previou...

journal_title：PharmacoEconomics

authors： Gidwani R,Russell LB

更新日期：2020-11-01 00:00:00

abstract：:Deterministic sensitivity analyses (DSA) remain important to interpret the effect of uncertainties in individual parameters on results of cost-effectiveness analyses. Classic DSA methodologies may lead to wrong conclusions due to a lack of or misleading information regarding marginal effects, non-linearity, likelihood...

journal_title：PharmacoEconomics

authors： Vreman RA,Geenen JW,Knies S,Mantel-Teeuwisse AK,Leufkens HGM,Goettsch WG

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:The process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking. OBJECTIVE:The overall objective of this research was ...

journal_title：PharmacoEconomics

authors： Petrou S,Rivero-Arias O,Dakin H,Longworth L,Oppe M,Froud R,Gray A

更新日期：2015-10-01 00:00:00

abstract：:A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

journal_title：PharmacoEconomics

authors： Oremus M,Aguilar SC

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Cost-effectiveness analyses worldwide assume that the price of any single drug increases with inflation. New guidance from the Pharmaceutical Management Agency in New Zealand suggests that, when it is known that a generic drug will be available in the near future, a best estimate of the lower price of the ge...

journal_title：PharmacoEconomics

authors： Hoyle M

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine. STUDY DESIGN AND METHODS:Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascula...

journal_title：PharmacoEconomics

authors： Casciano R,Doyle JJ,Chen J,Arikian S,Casciano J,Kugel H,Arocho R

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:To determine whether the use of risperidone in a US managed-care environment is associated with a reduction in the use of mental healthcare services. METHODS:Mental health service use and costs for patients with psychoses treated with risperidone versus those treated with conventional antipsychotic agents we...

journal_title：PharmacoEconomics

authors： Gianfrancesco F,Durkin MB,Mahmoud R,Wang RH

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:During the 1990s, a number of new cytotoxic agents with clinically relevant activity in non-small-cell lung cancer (NSCLC), and with a more favourable therapeutic index than drugs already in use, became available. Given the high prices of these new drugs and the large number of patients affected, it is impor...

journal_title：PharmacoEconomics

authors： Neymark N,Lianes P,Smit EF,van Meerbeeck JP

更新日期：2005-01-01 00:00:00

abstract：:The National Institute for Health and Care Excellence (NICE) is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. However, it can be argued that NICE has developed a more prominent international profile ...

journal_title：PharmacoEconomics

authors： Sculpher M,Palmer S

更新日期：2020-03-01 00:00:00

abstract：:A growing body of recent work has identified several problems with economic evaluations undertaken alongside controlled trials that can have potentially serious impacts on the ability of decision makers to draw valid conclusions. At the same time, the use of cost-effectiveness models has been drawn into question, due ...

journal_title：PharmacoEconomics

authors： McCabe C,Dixon S

更新日期：2000-05-01 00:00:00

abstract：BACKGROUND:Assessing the societal perspective in economic evaluations of new interventions requires estimates of indirect non-medical costs caused by the disease. Different methods exist for measuring the labor input function as a surrogate for these costs. They rarely specify the effect of health on labor and who gain...

journal_title：PharmacoEconomics

authors： Standaert B,Sauboin C,Leclerc QJ,Connolly MP

更新日期：2020-11-25 00:00:00

abstract：:Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...

journal_title：PharmacoEconomics

authors： Chongmelaxme B,Phisalprapa P,Manthaisong R,Dilokthornsakul P,Chaiyakunapruk N

更新日期：2019-02-01 00:00:00

abstract：:Until a few years ago, griseofulvin and ketoconazole were the only 2 oral agents available for the treatment of dermatophyte onychomycosis of the toenails. With the availability of the newer antifungal agents, such as itraconazole, terbinafine and fluconazole, the armamentarium of drugs available to treat onychomycosi...

journal_title：PharmacoEconomics

authors： Gupta AK

更新日期：1998-02-01 00:00:00

abstract：:As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the othe...

journal_title：PharmacoEconomics

authors： Tse G,Thompson D,Procyshyn RM

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Heart failure (HF) is a well-recognized public health concern and imposes high economic and societal costs. Decision analytic models exist for evaluating the economic ramifications associated with HF. Despite this, studies that appraise these modelling approaches for augmenting best-practice decisions remain...

journal_title：PharmacoEconomics

authors： Di Tanna GL,Bychenkova A,O'Neill F,Wirtz HS,Miller P,Ó Hartaigh B,Globe G

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:The apparent decrease in the rate of approval of new molecular entities has provoked extensive discussion and fears that the productivity of biopharmaceutical research and development has severely declined in recent years. OBJECTIVE:To investigate the extent to which traditional measures of innovative outpu...

journal_title：PharmacoEconomics

authors： Berndt ER,Cockburn IM,Grépin KA

更新日期：2006-12-01 00:00:00

abstract：BACKGROUND:In Ireland, all new drugs are considered for a formal pharmacoeconomic evaluation (PE) prior to a reimbursement decision. All evaluations are conducted by the National Centre for Pharmacoeconomics (NCPE). The objectives of this study were to describe the evaluation process and to examine the movement of drug...

journal_title：PharmacoEconomics

authors： McCullagh L,Barry M

更新日期：2016-12-01 00:00:00

abstract：:A survey of the prescribing of psychotropic drugs was carried out at the Psychiatric Hospital of Bahrain. This retrospective study on 60 inpatients of the Long Stay Ward revealed a man:woman ratio of 2.7. 91% of the men and 88% of the women were over 40 years old. 44 of the 60 patients had a diagnosis of schizophre...

journal_title：PharmacoEconomics

authors： El Hefny F,Al Haddad MK,Mathur V

更新日期：1992-03-01 00:00:00

abstract：:In this paper we consider the evolving American healthcare landscape and what it means for the use of economic evaluation of health interventions. We emphasise that use of economic evaluation in the US is unlikely to follow the European, Canadian or Australian models, which use cost effectiveness openly and explicitly...

journal_title：PharmacoEconomics

authors： Neumann PJ,Sullivan SD

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Administration and pharmaceutical companies around the price of new pharmaceuticals. The criteria currently...

journal_title：PharmacoEconomics

authors： Ochalek J,Wang H,Gu Y,Lomas J,Cutler H,Jin C

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Simulation models utilizing real-world data have potential to optimize treatment sequencing strategies for specific patient subpopulations, including when conducting clinical trials is not feasible. We aimed to develop a simulation model to estimate progression-free survival (PFS) and overall survival for fi...

journal_title：PharmacoEconomics

authors： Degeling K,Wong HL,Koffijberg H,Jalali A,Shapiro J,Kosmider S,Wong R,Lee B,Burge M,Tie J,Yip D,Nott L,Khattak A,Lim S,Caird S,Gibbs P,IJzerman M

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:International phase III studies (CHIB 201 and 352) showed that basiliximab, a high affinity chimeric monoclonal antibody interleukin-2 receptor antagonist, is highly effective in preventing acute rejection when used as immunoprophylaxis in patients receiving cyclosporin (Neoral). We conducted a cost evaluati...

journal_title：PharmacoEconomics

authors： Hasegawa T,Imai H,Miki S

更新日期：2003-01-01 00:00:00

abstract：:Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy in patients with LGS uncontrolled on one to t...

journal_title：PharmacoEconomics

authors： McCormack PL

更新日期：2012-03-01 00:00:00

abstract：:The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to ...

journal_title：PharmacoEconomics

authors： Yang H,Craig D,Epstein D,Bojke L,Light K,Bruce IN,Sculpher M,Woolacott N

更新日期：2012-04-01 00:00:00